IGF-1 LR3 (Long R3 IGF-1)

1. Overview

IGF-1 LR3 (Long R3 Insulin-like Growth Factor 1) is a synthetic 83-amino acid analog of human insulin-like growth factor 1 (IGF-1) that was engineered to have dramatically reduced binding to IGF binding proteins (IGFBPs), resulting in substantially increased biological potency and an extended functional half-life compared to native IGF-1. The analog incorporates two specific modifications to the native 70-amino acid IGF-1 sequence: a 13-amino acid N-terminal extension peptide (Met-Phe-Pro-Ala-Met-Pro-Leu-Ser-Ser-Leu-Phe-Val-Asn) prepended to the native sequence, and a single amino acid substitution of arginine for the native glutamic acid at position 3 of the mature IGF-1 sequence (Glu3Arg) [1][3][5].

Native IGF-1 is a 70-amino acid polypeptide (7,649 Da) with structural homology to proinsulin, first sequenced by Rinderknecht and Humbel in 1978 [14]. It is produced primarily by the liver in response to growth hormone stimulation and circulates largely bound to six high-affinity IGF binding proteins (IGFBP-1 through IGFBP-6), with approximately 99% of circulating IGF-1 bound -- predominantly in a ternary complex with IGFBP-3 and the acid-labile subunit (ALS). This extensive protein binding limits free IGF-1 bioavailability and results in a circulating half-life of only 12-15 minutes for unbound IGF-1 [11][12].

The development of IGF-1 LR3 arose from systematic structure-activity studies at the Cooperative Research Centre for Tissue Growth and Repair in Adelaide, Australia, during the late 1980s and early 1990s. Francis, Ballard, and colleagues identified that the N-terminal region of IGF-1, particularly the Glu3 residue, was critical for high-affinity IGFBP binding. By substituting arginine at this position and adding an N-terminal extension, they created a molecule that retained full IGF-1 receptor binding and activation capacity while escaping IGFBP sequestration [1][3][5]. The result was a research tool with approximately two to three times greater biological potency than native IGF-1 in cell culture and animal models, not because of enhanced receptor affinity, but because a far greater proportion of the analog remains in the free, bioactive state [1][6].

IGF-1 LR3 has found widespread use as a cell culture supplement in serum-free and low-serum media for mammalian cell lines, particularly in biopharmaceutical production. It has also been studied in preclinical models for intestinal growth, burn injury recovery, and protein catabolism. It has no approved therapeutic use in any jurisdiction and is prohibited by WADA under category S2 (Peptide Hormones, Growth Factors).

Type

Synthetic analog of IGF-1; modified growth factor

Amino Acids

83 residues (native IGF-1 is 70 aa)

Molecular Weight

~9,111 Da

Key Modifications

13-aa N-terminal extension + Glu3 to Arg3 substitution

IGFBP Binding

Dramatically reduced (greater than 100-fold lower affinity vs. native IGF-1)

Functional Half-life

~20-30 hours (vs. 12-15 minutes for native IGF-1)

Receptor

IGF-1R; PI3K/Akt and MAPK/ERK signaling

FDA Status

Not approved; research reagent and cell culture supplement only

WADA Status

Prohibited at all times (S2: Peptide Hormones, Growth Factors)

2. Molecular Structure

2.1 Native IGF-1 Structure

Human IGF-1 is a single-chain 70-amino acid polypeptide (molecular weight 7,649 Da) structurally homologous to proinsulin. It consists of four domains designated B, C, A, and D (from N- to C-terminus), with three intramolecular disulfide bonds (Cys6-Cys48, Cys18-Cys61, Cys47-Cys52) that stabilize its three-dimensional fold into a compact globular structure. The B and A domains correspond to the insulin B and A chains and contain the IGF-1 receptor binding surfaces [14].

Six high-affinity IGF binding proteins (IGFBP-1 through IGFBP-6) regulate IGF-1 bioavailability in vivo. The N-terminal region of IGF-1, particularly residues 1-16 of the B domain, contains the primary IGFBP binding determinants. The Glu3 residue specifically makes critical contacts with the hydrophobic binding pocket of multiple IGFBPs [11][12].

2.2 LR3 Modifications

IGF-1 LR3 differs from native IGF-1 in two ways:

13-amino acid N-terminal extension: The sequence Met-Phe-Pro-Ala-Met-Pro-Leu-Ser-Ser-Leu-Phe-Val-Asn is prepended to the native IGF-1 N-terminus. This extension sterically disrupts the spatial orientation of the N-terminal region relative to the IGFBP binding interface, reducing binding affinity by introducing conformational interference [1][3].

Glu3 to Arg3 substitution: Glutamic acid at position 3 of the mature IGF-1 sequence is replaced by arginine. This charge reversal (from negative to positive) at a critical IGFBP contact residue further reduces IGFBP binding affinity by greater than 100-fold compared to native IGF-1 [3][5].

Together, these modifications result in a molecule with:

• Full IGF-1 receptor binding and activation capacity (the receptor binding surfaces in the B and A domains are unperturbed)
• Dramatically reduced IGFBP binding (greater than 100-fold lower affinity for IGFBP-1, -2, -3, -4, -5, and -6)
• Extended functional half-life of approximately 20-30 hours in circulation (compared to 12-15 minutes for free native IGF-1)
• Higher free fraction in biological fluids, resulting in 2-3 times greater biological potency per unit dose

3. Mechanism of Action

IGF-1 LR3 exerts its biological effects through the same receptor as native IGF-1 -- the IGF-1 receptor (IGF-1R), a transmembrane receptor tyrosine kinase with structural homology to the insulin receptor [13][15].

3.1 IGF-1R Signaling Cascade

Upon binding to IGF-1R, the following signaling events occur:

1. Ligand binding induces conformational changes in the IGF-1R extracellular domain, activating the intracellular tyrosine kinase domains through trans-autophosphorylation
2. Phosphorylated IGF-1R recruits and phosphorylates insulin receptor substrates (IRS-1, IRS-2) and Shc adaptor proteins
3. Two major downstream pathways are activated:

PI3K/Akt/mTOR pathway (metabolic and survival signaling):

• IRS-1/2 recruit and activate phosphatidylinositol 3-kinase (PI3K)
• PI3K generates PIP3, which activates Akt (protein kinase B)
• Akt activates mTORC1, stimulating protein synthesis through S6K1 and 4E-BP1 phosphorylation
• Akt phosphorylates and inactivates pro-apoptotic factors (Bad, FoxO transcription factors), promoting cell survival
• Akt stimulates glucose uptake through GLUT4 translocation (insulin-like metabolic effect) [15]

MAPK/ERK pathway (proliferative signaling):

• Shc recruitment activates Grb2/SOS, which activates the Ras-Raf-MEK-ERK cascade
• ERK1/2 activation drives cell cycle progression, gene transcription, and cellular proliferation [13]

3.2 Enhanced Potency Mechanism

The enhanced biological potency of IGF-1 LR3 compared to native IGF-1 is not due to higher IGF-1R affinity -- receptor binding affinity is comparable between the two molecules. Rather, the advantage derives entirely from pharmacokinetic differences [1][6]:

• Native IGF-1 in biological systems is approximately 99% bound to IGFBPs, leaving only approximately 1% in the free, receptor-accessible state
• IGF-1 LR3 remains almost entirely in the free state due to its minimal IGFBP binding
• The result is that, at equal total concentrations, IGF-1 LR3 delivers approximately 100-fold more free ligand to IGF-1 receptors on target cells

In cell culture systems, this difference is amplified because cells secrete IGFBPs into the conditioned media over time, progressively sequestering added native IGF-1 but not LR3-IGF-1 [6]. Luthi et al. (1993) demonstrated that LR3-IGF-1 produced more sustained biological effects than Des(1-3)IGF-1 in ovine granulosa cell cultures, attributed to its greater IGFBP resistance maintaining bioactivity over longer incubation periods [6].

3.3 Cross-Reactivity

IGF-1 LR3 retains some cross-reactivity with the insulin receptor (IR), particularly the IR-A isoform, though at much lower affinity than for IGF-1R. At supraphysiological concentrations, this cross-reactivity can produce insulin-like metabolic effects including glucose uptake stimulation and hypoglycemia [15]. The hybrid IGF-1R/IR receptor also binds IGF-1 LR3.

4. Researched Applications

4.1 Cell Culture and Biopharmaceutical Production

Evidence level: Established laboratory reagent

The primary commercial application of IGF-1 LR3 is as a cell culture supplement for serum-free and low-serum media systems. In biopharmaceutical manufacturing, the shift toward chemically defined, animal-component-free media has created demand for recombinant growth factors that can replace the mitogenic and survival activity provided by fetal bovine serum. IGF-1 LR3 at concentrations of 20-100 ng/mL effectively supports proliferation and productivity of CHO cells, hybridoma cell lines, and other mammalian expression systems, outperforming native IGF-1 because it resists sequestration by cell-secreted IGFBPs in conditioned media [1][6].

4.2 Intestinal Growth and Gut Repair

Evidence level: Preclinical

Philipps et al. (1997) demonstrated that oral LR3-IGF-1 at 2.5 mg/kg/day stimulated intestinal mucosal growth in growth-retarded neonatal rats, increasing villus height, crypt depth, and mucosal protein content [8]. The peptide's resistance to IGFBP binding allowed sufficient free IGF-1R activation in the intestinal epithelium after oral administration. In a sepsis model, Huang and colleagues showed that subcutaneous LR3-IGF-1 attenuated cecal ligation and puncture-induced intestinal mucosal atrophy, preserved villus architecture, and reduced bacterial translocation across the compromised gut barrier [9].

4.3 Burn Injury and Protein Catabolism

Evidence level: Limited clinical data

In severely burned pediatric patients (greater than 40% total body surface area burns), LR3-IGF-1 administration reduced protein catabolism, improved nitrogen balance, and improved lean body mass retention. The catabolic response to severe burns involves massive protein breakdown mediated in part by IGF-1 resistance due to elevated IGFBP levels. LR3-IGF-1, by evading IGFBP sequestration, can maintain anabolic signaling even in the IGFBP-rich milieu of critical illness [2][9].

4.4 Muscle Growth and Anabolic Effects

Evidence level: Preclinical

In nitrogen-restricted rats, Tomas et al. (1991) demonstrated that LR3-IGF-1 was approximately three times more potent than native IGF-1 in promoting body weight gain and positive nitrogen balance after subcutaneous administration [2]. In hypophysectomized rats (lacking endogenous GH and thus endogenous IGF-1), LR3-IGF-1 restored growth at doses approximately one-third those required for native IGF-1 [1][10]. The anabolic effects include increased protein synthesis rates (via mTOR/S6K activation), reduced protein degradation (via PI3K/Akt-mediated suppression of the ubiquitin-proteasome pathway), and potential satellite cell proliferation.

4.5 Fetal Growth Restriction (2025)

Evidence level: Preclinical (negative result)

A 2025 study published in the American Journal of Physiology: Endocrinology and Metabolism tested LR3-IGF-1 infusion directly into the circulation of growth-restricted fetal sheep with placental insufficiency. LR3-IGF-1 did not improve fetal growth or attenuate circulating insulin or fetal glucose-stimulated insulin secretion. However, it significantly reduced circulating amino acids, particularly branched-chain amino acids, suggesting that IGF-1R activation drives amino acid uptake into tissues at the expense of circulating pools. The authors concluded that combined strategies to simultaneously maintain amino acid levels and elevate insulin or oxygen may be necessary to improve fetal growth in this population.

4.6 Cancer Biology Considerations

Evidence level: Biological concern based on extensive cancer biology literature

The IGF-1R signaling axis is extensively implicated in cancer biology. Elevated circulating IGF-1 levels are associated with increased risk of breast, prostate, colorectal, and lung cancers in epidemiological studies. IGF-1R activation promotes cell proliferation, inhibits apoptosis, and supports tumor metabolism [13][16]. The IGFBP system functions in part as a tumor-suppressive mechanism by limiting free IGF-1 bioavailability. Because IGF-1 LR3 is specifically designed to evade this regulatory system, its use raises significant theoretical oncogenic concerns that have not been addressed in long-term studies.

5. Clinical Evidence Summary

6. Dosing in Research

The following table summarizes doses used in published preclinical research and cell culture applications. No approved human therapeutic doses exist. These are not therapeutic recommendations.

7. Safety and Side Effects

7.1 Hypoglycemia

The most significant acute safety concern with IGF-1 and its analogs is hypoglycemia. IGF-1R activation stimulates glucose uptake in skeletal muscle and adipose tissue, and at higher concentrations, cross-reactivity with the insulin receptor amplifies this effect. Native recombinant IGF-1 (mecasermin, Increlex) carries a boxed warning for severe hypoglycemia. IGF-1 LR3, with its extended bioavailability and higher free fraction, would be expected to carry equal or greater hypoglycemic risk [15].

7.2 Theoretical Oncogenic Risk

The IGF-1R pathway is one of the most extensively studied signaling axes in cancer biology [13][16]. IGFBPs serve as a natural buffer system limiting IGF-1-driven cell proliferation and survival signaling. IGF-1 LR3 was specifically engineered to bypass this protective mechanism, raising substantial concerns about oncogenic promotion with repeated or chronic use. No long-term carcinogenicity studies of IGF-1 LR3 have been published.

7.3 Other Potential Adverse Effects

Based on the known pharmacology of IGF-1R activation and the documented adverse effects of recombinant IGF-1 (mecasermin) therapy:

• Injection site reactions and lipohypertrophy
• Headache and intracranial hypertension
• Jaw pain and tonsillar/adenoidal hypertrophy (prolonged use)
• Soft tissue edema
• Arthralgias
• Potential organ growth (organomegaly) with chronic supraphysiological exposure

7.4 Research Peptide Market Concerns

IGF-1 LR3 obtained through unregulated research peptide sources carries additional risks including potential contamination with endotoxins, misfolded protein, degradation products, or inaccurate concentration specifications. As a relatively large peptide (83 amino acids, approximately 9 kDa), manufacturing quality is more challenging than for smaller synthetic peptides, and improper folding of the three disulfide bonds could produce immunogenic or inactive material.

7.5 WADA Status

IGF-1 LR3 is prohibited at all times by WADA under category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). LC-MS/MS-based detection methods have been validated for identifying LR3-IGF-1 in urine and serum samples [17][18].

8. IGF-1 LR3 vs. IGF-1 DES vs. Native IGF-1

The three forms of IGF-1 available in research settings differ primarily in their IGFBP binding characteristics:

Native IGF-1 (70 aa, 7,649 Da): Full IGFBP binding. Approximately 99% bound in circulation. Half-life of 12-15 minutes (free) or 12-16 hours (in ternary complex with IGFBP-3/ALS). FDA-approved as mecasermin (Increlex) for severe primary IGF-1 deficiency.

IGF-1 LR3 (83 aa, 9,111 Da): Dramatically reduced IGFBP binding (greater than 100-fold lower affinity). Extended functional half-life of approximately 20-30 hours. Two to three times more potent than native IGF-1 in vivo. Not approved for any therapeutic use.

IGF-1 DES (67 aa, 7,365 Da): Truncated N-terminus (missing first 3 amino acids). Minimal IGFBP binding. Very short half-life (approximately 20-30 minutes) but approximately 10x higher potency per unit free concentration due to enhanced IGF-1R binding. Not approved for any therapeutic use.

IGF-1 LR3 represents the intermediate strategy: retaining the full IGF-1 receptor binding affinity of the native molecule while achieving extended bioavailability through IGFBP evasion. IGF-1 DES achieves even greater potency through enhanced receptor affinity but sacrifices duration due to rapid clearance.

9. Pharmacokinetics

IGF-1 LR3 achieves its extended functional half-life through dramatically reduced IGFBP binding (greater than 100-fold lower affinity) rather than through intrinsic changes in receptor binding or metabolic stability [1][3][5].

IGFBP evasion mechanism. Native IGF-1 is approximately 99% bound to IGFBPs in circulation, primarily in a ternary complex with IGFBP-3 and the acid-labile subunit (ALS), which extends the circulating half-life of total IGF-1 to 12-16 hours but limits the free fraction to approximately 1%. IGF-1 LR3, by contrast, remains almost entirely in the free state due to the Glu3Arg substitution and N-terminal extension eliminating critical IGFBP contact residues [11][12].

Functional half-life. The functional half-life of IGF-1 LR3 is approximately 20-30 hours, compared to 12-15 minutes for free native IGF-1. This extended activity reflects the slow clearance of the unbound peptide through renal filtration and proteolytic degradation, without the rapid IGFBP-mediated buffering and clearance mechanisms that control native IGF-1 [1][6].

Clearance. Primarily renal (glomerular filtration) followed by tubular reabsorption and proteolytic degradation. As a relatively large peptide (83 aa, approximately 9.1 kDa), renal filtration is slower than for smaller peptides. Hepatic proteolysis also contributes. Specific clearance values in humans have not been published.

Bioavailability (subcutaneous). No formal SC bioavailability studies in humans. In animal studies, subcutaneous LR3-IGF-1 at 0.3-3.0 mg/kg/day produced dose-dependent growth effects, with approximately 3x greater potency than equimolar native IGF-1, consistent with the higher free fraction [1][10].

Oral absorption. Philipps et al. (1997) demonstrated that oral LR3-IGF-1 at 2.5 mg/kg/day stimulated intestinal growth in neonatal rats, suggesting some degree of oral absorption from the neonatal GI tract (which is more permeable to large peptides than the adult GI tract). This finding is specific to the neonatal setting and does not imply practical oral bioavailability in adults [8].

Cell culture PK. In cell culture, LR3-IGF-1 at 20-100 ng/mL maintains bioactivity for 3-5 days in conditioned media because it is not progressively sequestered by cell-secreted IGFBPs (unlike native IGF-1, which loses activity as IGFBP concentrations rise). This sustained activity is the primary reason for its use as a serum-free media supplement [6].

10. Dose-Response Relationship

In vitro mitogenic dose-response. LR3-IGF-1 demonstrates a classic sigmoidal dose-response curve for DNA synthesis stimulation. In BALB/c 3T3 fibroblasts, it was approximately 3-fold more potent than native IGF-1 (EC50 approximately 3-fold lower) due to reduced IGFBP sequestration in the media [5].

In vivo growth dose-response (animal). In hypophysectomized rats (lacking endogenous GH/IGF-1), subcutaneous LR3-IGF-1 at 0.3-3.0 mg/kg/day produced dose-dependent increases in body weight, with potency approximately 3x that of native IGF-1. At equimolar doses, LR3-IGF-1 achieved approximately equivalent growth to 3x the dose of native IGF-1 [1][10].

Protein anabolism dose-response. In nitrogen-restricted rats, Tomas et al. (1991) demonstrated that LR3-IGF-1 improved nitrogen balance and reduced muscle protein breakdown in a dose-dependent manner, with potency approximately 3-fold greater than native IGF-1. The anabolic effects involve both increased protein synthesis (mTOR/S6K activation) and reduced protein degradation (PI3K/Akt-mediated suppression of ubiquitin-proteasome pathway) [2].

Sustained vs acute potency. Luthi et al. (1993) compared LR3-IGF-1 and Des(1-3) IGF-1 in ovine granulosa cells: Des(1-3) IGF-1 produced stronger initial responses (reflecting its approximately 10x higher IGF-1R affinity) but LR3-IGF-1 generated greater sustained effects over time (reflecting its approximately 20-30 hour functional half-life versus approximately 20-30 minutes for Des) [6].

Cell culture optimal concentrations. In serum-free media supplementation, LR3-IGF-1 is typically used at 20-100 ng/mL (approximately 2-11 nM), which is sufficient to support proliferation and productivity of most mammalian cell lines. Higher concentrations provide diminishing returns as IGF-1R becomes saturated.

No human dose-response data. No human dose-response studies exist. Community-reported doses in the research peptide market have no scientific basis.

11. Comparative Effectiveness

IGF-1 LR3 vs native IGF-1 (mecasermin/Increlex). LR3-IGF-1 is approximately 2-3x more potent per dose than native IGF-1 in vivo due to its dramatically higher free fraction. Native IGF-1 (mecasermin) is the only FDA-approved IGF-1 product, indicated for severe primary IGF-1 deficiency (Laron syndrome). LR3-IGF-1 has no approved therapeutic use. While LR3-IGF-1's higher free fraction provides greater potency, this same property increases the risk of hypoglycemia and removes the IGFBP safety buffer that limits IGF-1R overstimulation [11][12].

IGF-1 LR3 vs Des(1-3) IGF-1. Complementary engineering strategies: LR3 achieves sustained potency (approximately 20-30 h half-life) through IGFBP evasion with native receptor affinity; Des(1-3) achieves maximal instantaneous potency (approximately 10x higher IGF-1R affinity) but with short half-life (approximately 20-30 min). LR3 is preferred for sustained signaling applications; Des(1-3) for acute, high-potency applications [6][12 of Des file].

IGF-1 LR3 vs intact GH. GH stimulates IGF-1 production endogenously and has direct metabolic effects (lipolysis, insulin resistance). LR3-IGF-1 directly activates IGF-1R without requiring GH receptor signaling and does not produce the direct metabolic effects of GH. However, LR3-IGF-1 bypasses the IGFBP regulatory system that normally buffers IGF-1 bioactivity, raising oncogenic concerns [13][16].

Cell culture applications. LR3-IGF-1 is the preferred IGF-1 form for serum-free media supplementation due to its resistance to sequestration by cell-secreted IGFBPs, which progressively inactivate native IGF-1 in conditioned media. At 20-100 ng/mL, it effectively replaces the mitogenic activity of fetal bovine serum.

12. Enhanced Safety Profile

Hypoglycemia risk. The most significant acute safety concern. IGF-1R activation stimulates glucose uptake (GLUT4 translocation), and at high concentrations, LR3-IGF-1 cross-reacts with the insulin receptor. Native mecasermin carries a boxed warning for severe hypoglycemia. LR3-IGF-1, with its extended half-life and higher free fraction, would be expected to carry equal or greater hypoglycemic risk, with the additional concern that hypoglycemia would persist for hours rather than minutes due to the approximately 20-30 hour functional half-life [15].

Oncogenic risk. The most significant long-term safety concern. The IGF-1R axis is extensively implicated in cancer biology -- elevated circulating IGF-1 is associated with increased breast, prostate, colorectal, and lung cancer risk. IGFBPs function as a natural tumor-suppressive buffer by limiting free IGF-1 bioavailability. LR3-IGF-1 was specifically engineered to bypass this protective system, raising substantial theoretical oncogenic concerns. No carcinogenicity studies have been conducted [13][16].

No human safety database. LR3-IGF-1 has never been systematically tested for safety in humans. The limited clinical data (burn patients, intestinal studies) is insufficient for safety characterization. All use outside of controlled research settings is unvalidated.

Research peptide quality concerns. As a relatively large peptide (83 aa, 3 disulfide bonds), manufacturing quality is more challenging than for smaller peptides. Misfolded material (incorrect disulfide pairing) may be immunogenic, inactive, or produce unexpected effects. Endotoxin contamination, degradation products, and inaccurate concentrations are additional risks with unregulated products.

Potential organ overgrowth. Chronic supraphysiological IGF-1R activation can drive tissue hyperplasia and organomegaly. This risk is amplified with LR3-IGF-1 due to the sustained high free-fraction exposure. Potential tissues of concern include the heart (cardiomegaly), intestinal mucosa, and soft tissues [13].

WADA prohibition. Prohibited at all times under S2 (Peptide Hormones, Growth Factors). LC-MS/MS detection methods validated for urine and serum [17][18].

13. Related Peptides

See also: IGF-1 DES (Des(1-3) IGF-1), MGF (Mechano Growth Factor), Human Growth Hormone (hGH), HGH Fragment 176-191, CJC-1295, Ipamorelin, MK-677 (Ibutamoren)

14. References

1. [1] Francis GL, Ross M, Ballard FJ, et al. (1992). Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol. DOI PubMed
2. [2] Tomas FM, Knowles SE, Owens PC, et al. (1991). Effects of full-length and truncated insulin-like growth factor-I on nitrogen balance and muscle protein metabolism in nitrogen-restricted rats. J Endocrinol. PubMed
3. [3] King R, Wells JR, Krieg P, et al. (1992). Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3. J Mol Endocrinol. DOI PubMed
4. [4] Francis GL, Aplin SE, Milner SJ, et al. (1993). Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-II. Biochem J. PubMed
5. [5] Ballard FJ, Francis GL, Ross M, et al. (1987). Natural and synthetic forms of insulin-like growth factor-1 (IGF-1) and the potent derivative, destripeptide IGF-1: biological activities and receptor binding. Biochem Biophys Res Commun. PubMed
6. [6] Luthi C, Roth BV, Gosteli-Peter MA, et al. (1993). Recombinant Long-R3-IGF-I stimulates greater sustained secondary growth factor production than des(1-3)-IGF-I in ovine granulosa cells. J Endocrinol. PubMed
7. [7] Burrin DG, Wester TJ, Davis TA, et al. (1996). Orally administered IGF-I increases intestinal mucosal growth in formula-fed neonatal pigs. Am J Physiol. PubMed
8. [8] Philipps AF, Rao RK, Anderson GG, et al. (1997). Oral administration of Long R3 IGF-I stimulates intestinal growth in neonatal rats. Pediatr Res. PubMed
9. [9] Huang KF, Chung DH, Herndon DN. (1993). Insulin-like growth factor 1 (IGF-1) reduces gut atrophy and bacterial translocation after severe burn injury. Arch Surg. PubMed
10. [10] Tomas FM, Knowles SE, Chandler CS, et al. (1993). Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol. PubMed
11. [11] Jones JI, Clemmons DR. (1995). Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. DOI PubMed
12. [12] Hwa V, Oh Y, Rosenfeld RG. (1999). The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. DOI PubMed
13. [13] Pollak M. (2012). The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. DOI PubMed
14. [14] Rinderknecht E, Humbel RE. (1978). The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem. PubMed
15. [15] Siddle K. (2011). Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol. DOI PubMed
16. [16] Baxter RC. (2014). IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. DOI PubMed
17. [17] Thomas A, Kohler M, Strasburger CJ, et al. (2015). Determination of IGF-1 and qualitative detection of its analogues in plasma via immunoaffinity purification and LC-MS. Anal Bioanal Chem. DOI
18. [18] WADA. (2025). WADA Prohibited List - International Standard. World Anti-Doping Agency.